NASDAQ:NLTX

Neoleukin Therapeutics News Headlines

$12.42
+0.21 (+1.72 %)
(As of 04/14/2021 12:05 PM ET)
Add
Compare
Today's Range
$12.34
Now: $12.42
$12.68
50-Day Range
$11.26
MA: $12.04
$13.12
52-Week Range
$9.63
Now: $12.42
$18.13
Volume2,132 shs
Average Volume250,018 shs
Market Capitalization$525.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09

Headlines

Neoleukin Therapeutics (NASDAQ NLTX) News Headlines Today

SourceHeadline
Neoleukin Therapeutics (NASDAQ:NLTX) Shares Gap Down to $11.97Neoleukin Therapeutics (NASDAQ:NLTX) Shares Gap Down to $11.97
americanbankingnews.com - April 12 at 11:30 AM
Neoleukin Therapeutics (NLTX) "Buy" Rating Reiterated at MizuhoNeoleukin Therapeutics' (NLTX) "Buy" Rating Reiterated at Mizuho
americanbankingnews.com - April 12 at 12:46 AM
Carl Walkey Sells 1,800 Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) StockCarl Walkey Sells 1,800 Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Stock
americanbankingnews.com - April 8 at 7:50 PM
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Expected to Post Earnings of -$0.24 Per ShareNeoleukin Therapeutics, Inc. (NASDAQ:NLTX) Expected to Post Earnings of -$0.24 Per Share
americanbankingnews.com - April 6 at 10:18 PM
Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 4.3%Neoleukin Therapeutics (NASDAQ:NLTX) Trading Down 4.3%
americanbankingnews.com - April 6 at 1:02 PM
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) SVP Sells $21,528.00 in StockNeoleukin Therapeutics, Inc. (NASDAQ:NLTX) SVP Sells $21,528.00 in Stock
americanbankingnews.com - April 2 at 7:52 PM
Head-To-Head Comparison: Neoleukin Therapeutics (NASDAQ:NLTX) and Milestone Pharmaceuticals (NASDAQ:MIST)Head-To-Head Comparison: Neoleukin Therapeutics (NASDAQ:NLTX) and Milestone Pharmaceuticals (NASDAQ:MIST)
americanbankingnews.com - March 31 at 8:44 AM
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) to Post Q1 2022 Earnings of ($0.35) Per Share, Piper Sandler ForecastsNeoleukin Therapeutics, Inc. (NASDAQ:NLTX) to Post Q1 2022 Earnings of ($0.35) Per Share, Piper Sandler Forecasts
americanbankingnews.com - March 31 at 3:12 AM
Research Analysts Set Expectations for Neoleukin Therapeutics, Inc.s Q1 2022 Earnings (NASDAQ:NLTX)Research Analysts Set Expectations for Neoleukin Therapeutics, Inc.'s Q1 2022 Earnings (NASDAQ:NLTX)
americanbankingnews.com - March 29 at 2:34 AM
Neoleukin Therapeutics, Inc.s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call TranscriptNeoleukin Therapeutics, Inc.'s (NLTX) CEO Jonathan Drachman on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - March 27 at 3:45 AM
Neoleukin Therapeutics (NASDAQ:NLTX) Announces Quarterly  Earnings Results, Misses Estimates By $0.03 EPSNeoleukin Therapeutics (NASDAQ:NLTX) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS
americanbankingnews.com - March 26 at 11:48 AM
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Receives Consensus Recommendation of "Buy" from AnalystsNeoleukin Therapeutics, Inc. (NASDAQ:NLTX) Receives Consensus Recommendation of "Buy" from Analysts
americanbankingnews.com - March 26 at 2:40 AM
Neoleukin Therapeutics Announces Year End 2020 Financial ResultsNeoleukin Therapeutics Announces Year End 2020 Financial Results
finance.yahoo.com - March 25 at 8:47 PM
 Brokerages Anticipate Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) to Announce -$0.21 EPS Brokerages Anticipate Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) to Announce -$0.21 EPS
americanbankingnews.com - March 20 at 4:10 PM
Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
finance.yahoo.com - March 18 at 12:11 PM
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences ConferenceNeoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 10:44 AM
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology DaysNeoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
finance.yahoo.com - February 5 at 10:46 AM
Neoleukin Therapeutics: De Novo Protein Design PlatformNeoleukin Therapeutics: De Novo Protein Design Platform
seekingalpha.com - February 5 at 5:46 AM
SHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLCSHAREHOLDER ALERT: Investigation of Neoleukin Therapeutics Announced by Holzer & Holzer, LLC
finance.yahoo.com - January 25 at 5:29 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTXSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neoleukin Therapeutics, Inc. - NLTX
finance.yahoo.com - January 24 at 6:18 AM
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Neoleukin Therapeutics, Inc. (NLTX) InvestigationBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Neoleukin Therapeutics, Inc. (NLTX) Investigation
finance.yahoo.com - January 14 at 7:14 PM
Neoleukin Gets FDA Clinical Hold Letter Related To IND Of NL-201 - Quick FactsNeoleukin Gets FDA Clinical Hold Letter Related To IND Of NL-201 - Quick Facts
nasdaq.com - January 8 at 12:53 PM
Why Neoleukin Therapeutics Stock Is Down TodayWhy Neoleukin Therapeutics Stock Is Down Today
fool.com - January 8 at 12:53 PM
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
finance.yahoo.com - January 8 at 12:53 PM
U.S. FDA puts early-stage trial of Neoleukin potential cancer treatment on holdU.S. FDA puts early-stage trial of Neoleukin potential cancer treatment on hold
finance.yahoo.com - January 8 at 12:53 PM
Neoleukin Therapeutics to Present at J.P. Morgan Healthcare ConferenceNeoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 11:35 AM
Neoleukin Therapeutics, Inc.Neoleukin Therapeutics, Inc.
fool.com - December 24 at 10:36 PM
Neoleukin: New Phase 1 Initiation, Strong Managerial Expertise, And Promising TechnologyNeoleukin: New Phase 1 Initiation, Strong Managerial Expertise, And Promising Technology
seekingalpha.com - December 18 at 1:28 PM
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for CancerNeoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
finance.yahoo.com - December 10 at 9:22 AM
Neoleukin Therapeutics Inc.Neoleukin Therapeutics Inc.
barrons.com - November 27 at 12:31 AM
Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare ConferenceNeoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference
finance.yahoo.com - November 23 at 8:21 AM
How One Company Pivoted From Cancer To Coronavirus And Designed A Virus-Blocking Drug In 10 WeeksHow One Company Pivoted From Cancer To Coronavirus And Designed A Virus-Blocking Drug In 10 Weeks
forbes.com - November 19 at 1:12 PM
Did Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Insiders Buy Up More Shares?Did Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Insiders Buy Up More Shares?
finance.yahoo.com - November 18 at 9:48 AM
Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceNeoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
finance.yahoo.com - November 11 at 12:30 PM
Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)
finance.yahoo.com - November 10 at 12:32 PM
Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate UpdateNeoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update
finance.yahoo.com - November 9 at 9:53 AM
Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In VivoNeoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo
finance.yahoo.com - November 5 at 3:21 PM
Neoleukin Therapeutics Appoints Holly K. Vance as  General CounselNeoleukin Therapeutics Appoints Holly K. Vance as General Counsel
finance.yahoo.com - October 20 at 8:21 AM
NEOLEUKIN TERAP. -,000001 (6AP.MU)NEOLEUKIN TERAP. -,000001 (6AP.MU)
au.finance.yahoo.com - October 14 at 4:43 AM
Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment ConferenceNeoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
finance.yahoo.com - September 9 at 8:58 AM
What Type Of Shareholders Own The Most Number of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares?What Type Of Shareholders Own The Most Number of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) Shares?
finance.yahoo.com - August 20 at 3:12 PM
Neoleukin (NLTX) Upgraded to Buy: What Does It Mean for the Stock?Neoleukin (NLTX) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - August 19 at 1:14 PM
Neoleukin Therapeutics (NLTX) Investor Presentation - SlideshowNeoleukin Therapeutics (NLTX) Investor Presentation - Slideshow
seekingalpha.com - August 16 at 4:28 PM
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2020 Results - Earnings Call TranscriptNeoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 12 at 11:11 PM
Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate UpdateNeoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update
finance.yahoo.com - August 12 at 6:11 PM
Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth ConferenceNeoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference
finance.yahoo.com - August 6 at 9:27 AM
Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020
finance.yahoo.com - August 5 at 12:59 PM
Were Hedge Funds Right About Neoleukin Therapeutics, Inc. (NLTX)?Were Hedge Funds Right About Neoleukin Therapeutics, Inc. (NLTX)?
finance.yahoo.com - August 3 at 1:36 PM
Is Neoleukin Therapeutics a Buy?Is Neoleukin Therapeutics a Buy?
finance.yahoo.com - July 15 at 8:34 AM
Neoleukin (NLTX) Moves to Buy: Rationale Behind the UpgradeNeoleukin (NLTX) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - July 3 at 2:27 PM
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.